Medtronic says it's not affected by the latest federal crackdown on tax inversions

Due to rumbles of an impending tax inversion deal between Pfizer ($PFE) and Allergan ($AGN), the feds are once again trying to make life difficult for companies like Ireland's Medtronic ($MDT) that moved their headquarters abroad to gain tax advantages. Medtronic said the latest rule changes won't have a material financial impact on the company. A previous rule change did not squash its $50 billion deal to acquire Covidien, though it did force the company to take on more debt than anticipated to finance the transaction. More